Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | MMP2 | P08253 | 4/20 | 0.34 |
| ▸ | MMP1 | P03956 | 2/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17977029 | 0.85 | CPN1 (0.33) | MMP2MMP1MMP3 | |
| SCHEMBL14861661 | 0.85 | GAA (0.31) | GLA | |
| SCHEMBL14862424 | 0.84 | MEN1 (0.30) | EPHX2 | |
| SCHEMBL14861752 | 0.83 | MAPT (0.30) | — | |
| SCHEMBL17977048 | 0.82 | MAPT (0.32) | MMP2MMP1MMP3 | |
| SCHEMBL14862426 | 0.78 | HPGD (0.38) | ALDH1A1LMNAHPGD | |
| SCHEMBL27818840 | 0.78 | ALDH1A1 (0.64) | EPHX2ALDH1A1NPSR1MMP2CA12 | |
| SCHEMBL17979128 | 0.77 | EPHX1 (0.41) | ALDH1A1MMP2MMP1MMP3EPHX1 | |
| SCHEMBL14535008 | 0.77 | CTSK (0.35) | EPHX2GLA | |
| SCHEMBL11319719 | 0.76 | EPHX2 (0.41) | EPHX2ALDH1A1NPSR1MMP2MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180237441-A1 | Chemical Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-08-23 | — | — | US | disclosed |
| CN-108349984-A | The derivative of 1- Phenylpyrrolidine -2- ketone as PERK inhibitor | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | 2018-07-31 | — | — | CN | disclosed |
| EP-3350185-A1 | 1-PHENYLPYRROLIDIN-2-ONE DERIVATIVES AS PERK INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2018-07-25 | — | — | EP | disclosed |
| WO-2017046737-A1 | 1-PHENYLPYRROLIDIN-2-ONE DERIVATIVES AS PERK INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017046737-A1 | 1-PHENYLPYRROLIDIN-2-ONE DERIVATIVES AS PERK INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-03-23 | — | — | WO | disclosed |
| US-6492392-B1 | INHIBITING TUMOR CELL PROLIFERATION | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-12-10 | — | — | US | disclosed |
| WO-2001085716-A1 | 2-PIPERIDONE COMPOUNDS FOR THE TREATMENT OF CANCER | KYOWA HAKKO KOGYO CO., LTD (JP) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180237441-A1 | Chemical Compounds | PSEN1, IRS1, CPT1A | EPHX2 4030/4885ALDH1A1 3289/4885GLA 4117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.